That's crucial, because the way a protein in the body folds determines if a pharmaceutical will have the ability to bind to that protein and work. To put it simply, we need to know how these proteins fold if we want a drug to work. Historically, this has actually been an experimental process (what is the legacy report predicting). Now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it a lot easier to create drugs that do what they're created to do. This was a breakthrough practically nobody observed. However it's going to have profound ramifications for curing disease. I anticipate that Alpha, Fold will be 98% accurate by the end of 2021.
And, obviously, there will be a lot of investment chances in this area, too. Moving topics It's going to be an excellent year for bitcoin. I'm bullish on it in 2021 (diplomatic relations). That stated, I still believe bitcoin will continue to be volatile. We're close to all-time highs. I wouldn't be shocked if it drew back possibly substantially prior to going higher - legacy report prediction. I've been covering bitcoin for a long time now. Among the very first research reports I ever released was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that initial suggestion, I titled my report "What's the Big Offer With Bitcoin?" That shows you where the conversation was at the time. We were mainly informing readers. However that's not the huge question any longer. Now we're seeing institutional money finally take an interest in bitcoin. Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, specific niche enterprise. Mass, Mutual is a trusted 170-year-old institution. So think about that. In five years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
Which's a huge reason I'm bullish on it this year. tech stocks. Regards, Jeff Brown, Editor, The Bleeding Edge I have a reward forecast 2020 was a record year for IPOs. 552 U.S. business went public the most in more than 20 years. These companies raised a total of $172 billion. That's an all-time high beating the previous yearly record by 43%. I predict 2021 will be another record year in IPOs. There are so many fantastic private business on the brink of hitting the public markets And I have actually been dealing with a brand-new method for you to invest even before these business go public.
This opportunity has been constructing over the last few years. I can't wait to tell you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to learn all the information. Go right here to reserve your spot totally free.
Emma Walsh here, handling editor of the Diary. Routine Journal readers know that tech isn't our typical beat (jeff brown top biotech stock 2021). And when it comes to tech investing, we leave it to the specialists. Fortunately, we have numerous such specialists in our Rolodex. Our colleague Jeff Brown will be familiar to our longtime readers. He is one of the most accomplished tech investing specialists we know (united arab emirates). In fact, he had numerous triple-digit returns in his Brownstone Research study portfolios in 2015. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to take an appearance at the huge image and predict what's just around the corner.
That includes things like 5G networks, biotech, expert system, and a lot more. These trends are experiencing rapid growth and developing extraordinary opportunities for investors. I wish to ensure all our readers are prepared for what's next. And with that in mind, let me draw the picture of what I see being available in the next 12 months Our brand-new 5G (fifth-generation) wireless networks are a topic I've been covering for years now. bleeding edge. But regardless of what lots of readers might believe, this is a pattern that's simply beginning. Although the COVID-19 pandemic disrupted supply chains in 2015, an impressive 250 million 5G-enabled devices were still sold.
And all of this eventually caused Apple delaying the release of the 5G-enabled i, Phone 12 by 2 months (what is the legacy report predicting). Losing two months of production and sales really affects how many 5G devices are offered in the calendar year. When you consider all of that, selling 250 million systems is amazing. More importantly, the delays triggered by the pandemic produced a lots of bottled-up demand. Which need is now going to be pressed into 2021. In truth, I predict that more than 500 million 5G gadgets will be delivered in 2021 - jeff brown tech stock 2021. And that's not my only 5G forecast When I've talked about 5G in the past, I have actually explained its three various stages.
In Phase Two, 5G gadgets go on sale. 5G phones and other items start to reach customers. And in Phase 3, 5G services begin to be provided (jeff bezos). That's when we start to see applications working on 5G networks. Believe of things like massive multiplayer video games over a cellphone. That's not possible with 4G. It will be with 5G. And my 2nd 5G prediction for 2021 is that we will start Phase Three by this summer season. This begins something of a virtuous cycle: The majority of people do not truly care about the innovation. However they will care if there are interesting applications that can only be accessed with a 5G phone.
That leads to more 5G apps being developed. In fact, 5G is going to open up a suite of amazing applications: self-driving cars, the Internet of Things, robotic surgical treatment, and more. All of these innovations need 5G. The financial investment opportunities going forward will be huge. Stepping away from 5G, the next important technology I foresee in 2021 is CRISPR hereditary editing. CRISPR represents "clustered routinely interspaced short palindromic repeat." It's a mouthful. However it's one of the most exciting developments in biotechnology. At a high level, CRISPR is an innovation that can modify our genetic makeup as if it were software application.
The program can crash or not operate properly. CRISPR utilizes a similar idea however with our hereditary code. "Typos" in our genome can cause disease. CRISPR can remedy these "typos." For several years, CRISPR was mainly a niche technology that wasn't well understood. And during that time, there were actually just 3 business operating in this space. But things are altering. CRISPR is no longer simply theoretical. We're seeing real results. We're dealing with diseases and seeing that this innovation just works. And as an outcome, a "second crop" of early-stage CRISPR companies is going public and providing incredible returns. This whole industry is effectively a greenfield opportunity.
There's room for numerous business to exist in this area. legacy report prediction. And there will be more. That's my forecast for CRISPR in 2021. I predict that two or three more hereditary modifying companies will hold their IPOs. Sticking with biotechnology, we are seeing incredible things taking place at the merging of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, simply revealed at the end of 2020 that its latest Alpha, Fold software can accurately predict the folding of a protein based entirely on its amino acid sequence with 92. 4% accuracy. That is essential due to the fact that the method a protein in the human body folds identifies if a pharmaceutical will have the ability to bind to that protein and be reliable.
Historically, this has actually been a trial-and-error process. And now, Alpha, Fold can anticipate protein folding with 92. 4% precision. That's going to make it much easier to create drugs that do what they're created to do. And here's my next prediction. I forecast that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not simply one however several drug therapies produced utilizing this innovation. This was among those breakthroughs that nearly nobody saw. But it's going to have extensive ramifications for curing disease. And, of course, there will be a lot of financial investment opportunities in this space, too.
It's going to be a good year for bitcoin. I'm bullish on it in 2021. That stated, I still think bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be amazed if it pulled back maybe considerably before going higher. I have actually been covering bitcoin for a very long time now. One of the first research reports I ever published was on bitcoin - exponential growth. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ roi for any person who followed my suggestion. But at the time of that preliminary recommendation, I titled my report, "What's the Big Deal With Bitcoin?" That shows you where the conversation was at the time.
But nobody is asking that question any longer. Now, we're seeing institutional cash finally taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, niche enterprise. the legacy report prediction. Mass, Mutual is a 150-year-old institution. So think about that. In five years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a big reason that I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more bonus offer forecast In 2021, we're going to have another record year in IPOs. One site reports that Jeff Brown deserves about $27. 5 million and claims the details depends on date since February 2021, however we could not individually validate this claim. Provided Jeff Brown's past, he likely has a significant net worth, however we can't hammer down an accurate figure at this minute. Brown is best understood for his sage-like ability to select winning technology stocks. He spent more than 25 years researching innovation companies like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience gives him an excellent viewpoint on the market. He's always on the hunt for brand-new chances, and he shares much of his best picks in the Future Report.
That's high praise, however it's not absurdly reasoned. Brown has an outstanding credibility as a stock-picker, and he successfully anticipated a few of the greatest financial occasions of the previous twenty years. Although he doesn't appear to launch his picks to the general public, the service's success is a direct indication of Brown's stock-picking expertise. Nobody on Wall Street gets it ideal every time, however Jeff Brown's accurate predictions have actually made him legions of dedicated followers. That states a lot about his ability. The Future Report is released by Brownstone Research study, a prominent monetary research study publisher. Brownstone Research study offers a number of research services with a variety of expertises - second wave.
The business is also associated with Bonner & Partners, another well-respected research publisher - white house. On its website, Brownstone says its mission is to supply retail investors with professional-grade research: "For too long, the best financial investment research has not been readily available to private financiers. It has actually been normally reserved for investment banks, hedge funds, personal equity, and high-net-worth clients. biotech stock. The objective of Brownstone Research study is to make that sort of proprietary research available to any financiers aiming to acquire an edge in the marketplaces. The goal is easy to provide unique and successful investment research discovered nowhere else." -Brownstone Research study site excerpt from the Jeff Brown is the founder of Brownstone Research, and he also works as the firm's Chief Financial investment Analyst.
With Brown guiding the ship, Brownstone Research is a powerhouse publisher with lots to use its customers. After years of steady success at the helm of top-tier business like Tesla and Area, X, Elon Musk is a household name throughout the majority of America. If you know even a little bit about the market, you understand that he has a credibility as a King Midas of sorts. jeff brown biotech stock pick for 2020. Whatever he touches relies on gold! Jeff is aware of Elon Musk's executive prowess, so he constantly has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge project.
In reality, Brown believes S.A.V. last year. could be "the greatest trend of the 2020s, and he's not alone. Inspect out these quotes from other well-known S.A.V. bulls: Elon's next big act will be marrying 2 innovative technologies: expert system and electric vehicles. Musk hopes the combination will assist him establish the first fully-autonomous, self-driving cars ever. It's nothing except the automotive market's Holy Grail. As you understand, electrical automobiles and self-driving car stocks have actually been huge this year, but the Wall Street machine has actually approved buzz without much tangible result. In spite of an extreme increase in competitors over the previous few years, Brown still believes Musk has the best opportunity of putting all of it together.
tech might be the magic string that connects all of it together. S.A.V. means Shared Autonomous Vehicle, and it could be the future of transport. Basically, this technology would permit you to rent out your vehicle as a self-governing, self-driving taxi when you're not using it. You merely leave the automobile and press a button on an app that tells the vehicle to "join the fleet." Next thing you understand, you're unwinding on your couch while your automobile shuttles ride-sharers around town. Best of all, you get to keep a large chunk of the profits. It sounds insane, however it might be closed than you think.